Daxor Expands Its BVA-100™ Blood Volume Diagnostic to Two New Hospital Systems Adding to Sales Momentum
Daxor (DXR) announces expansion of its ezBVA Lab blood volume analysis service to two new health systems. The expansion includes an Arizona-based multi-campus medical center for outpatient nephrology care and a regional health network serving Southwest Iowa, Nebraska, Minnesota, and North Dakota for heart failure outpatient management.
The ezBVA Lab service provides cost-effective blood volume analysis with minimal initial investment and broad reimbursement coverage. The company reports this expansion contributes to their strongest quarter ever in terms of revenue and year-over-year growth.
Daxor (DXR) annuncia l'espansione del suo servizio di analisi del volume sanguigno ezBVA Lab a due nuovi sistemi sanitari. L'espansione include un centro medico multi-sede in Arizona per la cura nefrologica ambulatoriale e una rete sanitaria regionale che serve il sud-ovest dell'Iowa, il Nebraska, il Minnesota e il Dakota del Nord per la gestione ambulatoriale dell'insufficienza cardiaca.
Il servizio ezBVA Lab offre un'analisi del volume sanguigno a un costo contenuto con un investimento iniziale minimo e una vasta copertura di rimborso. L'azienda riporta che questa espansione contribuisce al suo trimestre più forte di sempre in termini di fatturato e crescita anno su anno.
Daxor (DXR) anuncia la expansión de su servicio de análisis de volumen sanguíneo ezBVA Lab a dos nuevos sistemas de salud. La expansión incluye un centro médico de múltiples campus en Arizona para atención nefrológica ambulatoria y una red de salud regional que atiende el suroeste de Iowa, Nebraska, Minnesota y Dakota del Norte para la gestión ambulatoria de la insuficiencia cardíaca.
El servicio ezBVA Lab proporciona un análisis de volumen sanguíneo rentable con una inversión inicial mínima y una amplia cobertura de reembolso. La empresa informa que esta expansión contribuye a su mejor trimestre en términos de ingresos y crecimiento interanual.
Daxor (DXR)는 ezBVA Lab 혈액량 분석 서비스를 두 개의 새로운 의료 시스템으로 확장한다고 발표했습니다. 확장은 애리조나에 위치한 다 캠퍼스 의료 센터의 외래 신장 치료 및 심부전 외래 관리를 위해 남서부 아이오와, 네브래스카, 미네소타 및 노스다코타를 서비스하는 지역 건강 네트워크를 포함합니다.
ezBVA Lab 서비스는 최소한의 초기 투자와 넓은 환불 범위를 통해 비용 효율적인 혈액량 분석을 제공합니다. 이 확장은 수익 및 전년 대비 성장 측면에서 회사의 가장 강력한 분기에 기여했다고 보고되었습니다.
Daxor (DXR) annonce l'expansion de son service d'analyse du volume sanguin ezBVA Lab à deux nouveaux systèmes de santé. L'expansion comprend un centre médical multicampus basé en Arizona pour les soins ambulatoires en néphrologie et un réseau de santé régional desservant le sud-ouest de l'Iowa, le Nebraska, le Minnesota et le Dakota du Nord pour la gestion ambulatoire de l'insuffisance cardiaque.
Le service ezBVA Lab fournit une analyse du volume sanguin rentable avec un investissement initial minimal et une large couverture de remboursement. L'entreprise rapporte que cette expansion contribue à son meilleur trimestre jamais réalisé en termes de revenus et de croissance d'une année sur l'autre.
Daxor (DXR) kündigt die Expansion seines Blutvolumenanalyse-Dienstes ezBVA Lab in zwei neue Gesundheitssysteme an. Die Expansion umfasst ein mehrere Standorte umfassendes medizinisches Zentrum in Arizona für die ambulante Nephrologiepflege und ein regionaler Gesundheitsverbund, der den Südwesten von Iowa, Nebraska, Minnesota und Norddakota für die ambulante Behandlung von Herzinsuffizienz bedient.
Der ezBVA Lab-Service bietet eine kostengünstige Blutvolumenanalyse mit minimalen Anfangsinvestitionen und umfassender Erstattung. Das Unternehmen berichtete, dass diese Expansion zu seinem stärksten Quartal aller Zeiten in Bezug auf Einnahmen und Jahr-zu-Jahr-Wachstum beiträgt.
- Expansion to two new major health systems
- Company reports best quarter ever in revenue and year-over-year growth
- Broad reimbursement coverage across hospitals and ambulatory care settings
- Minimal initial investment required for healthcare providers
- None.
Insights
The expansion of Daxor's BVA-100™ diagnostic service to two new healthcare systems marks a significant milestone in their commercialization strategy. The ezBVA Lab service offers a compelling value proposition with minimal upfront investment and broad reimbursement coverage. The adoption in both nephrology and heart failure settings demonstrates the versatility and clinical utility of blood volume analysis. These implementations could drive substantial recurring revenue through test volumes, particularly given the chronic nature of both conditions requiring regular monitoring. The geographic expansion across multiple states and the multi-campus approach suggests strong market penetration potential.
This expansion represents meaningful revenue growth potential for Daxor, particularly given the CEO's statement about positioning for their best quarter ever in terms of revenue and year-over-year growth. The ezBVA Lab service model is strategically sound, lowering barriers to adoption while ensuring recurring revenue streams. The focus on outpatient care in both nephrology and cardiology departments presents significant market opportunities, as these are high-volume specialties with substantial patient populations. The broad reimbursement coverage enhances the likelihood of sustained adoption and utilization. For a company with a
Healthcare Providers Embrace Blood Volume Analysis (BVA) in Nephrology and Heart Failure Outpatient Care
Oak Ridge, TN, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces expansion of its ezBVA Lab service to two new health systems. Daxor's ezBVA Lab provides cost-effective blood volume analysis, offering comprehensive sample processing with minimal initial investment. The service has broad reimbursement coverage across hospitals and ambulatory care settings.
New wins include:
- A major Arizona-based multi-campus medical center has adopted our BVA technology for outpatient nephrology care with further departments to follow in 2025.
- A regional health network serving communities across Southwest Iowa, Nebraska, Minnesota, and North Dakota has agreed to implement BVA for heart failure outpatient management.
“Our BVA platform is a critical diagnostic tool that redefines outpatient care by providing real-time insights into a patient's volume status. By enabling early detection of fluid imbalances and cardiovascular risks, BVA empowers clinicians to intervene proactively, potentially preventing costly hospitalizations, reducing emergency interventions, and personalizing patient treatment strategies," said John Jefferies, Daxor's Chief Medical Officer.
“The continued sales growth that the company is experiencing has positioned us for our best quarter ever in terms of revenue and year-over-year growth reflecting the focus of our commercialization team and the increasing customer engagement driven by our clinical education team,” said Michael Feldschuh, Daxor’s CEO and President.
About Daxor Corporation
Daxor Corporation (Nasdaq: DXR), is the global leader in blood volume measurement technology focused on blood volume testing innovation. We developed and market the BVA-100™ (Blood Volume Analyzer), the only diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000+ tests have been performed at leading hospital centers across the U.S., enhancing hospital performance metrics in a broad range of surgical and medical conditions, including significantly reducing mortality and readmissions in heart failure and critical care. Daxor has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the U.S. Department of Defense. Daxor's mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor’s vision is optimal blood volume for all. For more information, please visit our website at Daxor.com. Sign up to receive news on Daxor’s innovative technology HERE.
Forward-Looking Statements
Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact:
Bret Shapiro
Sr. Managing Partner, CORE IR
1-516-222-2560
brets@coreir.com
FAQ
What new healthcare systems has Daxor (DXR) expanded its BVA-100 diagnostic to in December 2023?
How does Daxor's ezBVA Lab service benefit healthcare providers?
What is the financial impact of the new expansions on Daxor (DXR)?
What medical applications is Daxor's BVA-100 being implemented for in the new health systems?
